Our Technology

The MSI-TX thin film (shown above) stabilizes biologic materials (live virus and bacterial-based vaccines, as well as antibody-based therapeutics) in a thermostable film matrix for ease of shipment, storage, and administration in both developing and industrialized countries. All materials used to generate these thin films have GRAS (generally recognized as safe) status from the US FDA. Our thin film has been validated with influenza and Ebola vaccines, as well as live bacteria at room temperature (20°C) for extended periods of time (6 months to 3 years).

Due to the lightweight, compact, and temperature stability of the MSI-TX thin film, this technology would greatly reduce the need for specialized resources and simplify the logistics for transport, distribution, and storage of vaccines and therapeutics. As an example, transport and storage of the TB vaccine (BCG) within our thin film would be approximately 40 times lighter and require 46.5 times less space than current packaging methods**. Additionally, the thermostable nature of our thin film enables it to maintain the therapeutic efficacy of its payload, even at extreme temperatures. 

Transport and storage of vaccines and therapeutics within our MSI-TX thin film could enable the global pharmaceutical supply chain to transition from temperature-controlled cargo containers shipped in costly and resource-limited jumbo jets and cargo ships, to sterile envelopes mailed with a postage stamp.

Furthermore, manufacturing our thin film is adaptable to a variety of biologics, requires a very short processing time (~8 hours), and is easily transferable to industrialized and developing countries. The MSI-TX thin film has been validated with: 

· Live Recombinant Adenovirus

· Live Influenza 

· Live E coli

· Recombinant RSV (Respiratory Syncytial Virus)

· Recombinant HSV (Herpes Simplex Virus)

· Recombinant DNA

· …and more

MSI-TX can be used to directly deliver vaccines and therapeutic payloads through buccal (inside the cheek) or sub-lingual (under the tongue) routes. Alternatively, our thin films can be rehydrated in order to recover the therapeutic payload in an aqueous solution, which can then be administered via various routes. These routes of administration can improve the potency of biologics without using needles, for wholly non-invasive vaccine and drug delivery. We are also optimizing the MSI-TX thin film for rapid and/or continuous release of therapeutic payloads, further increasing its potential applications in the clinic.

If you would like to discuss any of our results or are interested in studying the MSI-TX thin film for your company's technology, please contact us using the link below.

**Based on packaging data from the World Health Organization on How to Calculate Vaccine Volumes and Cold Chain Capacity Requirements